The main directions and prospects in polycystic ovary syndrome treatment

The main directions and prospects in polycystic ovary syndrome treatment

The article is devoted to the actual gynecological problem of women of reproductive age-polycystic ovarian syndrome (PCOS) and the possibilities of its pharmacotherapy. Difficulties in choosing the treatment of the disease are the need to take into account all clinical manifestations, not limited to...

Full description

Bibliographic Details
Main Authors:	A. N. Useinova, E. A. Egorova, E. A. Yelisheva, А. М. Beitullaev, K. N. Koryanova
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Siberian Branch Publishing House 2021-12-01
Series:	Сибирский научный медицинский журнал
Subjects:	polycystic ovarian syndrome combined oral contraceptives metformin glucagon-like peptide-1 receptor agonists
Online Access:	https://sibmed.elpub.ru/jour/article/view/694

Similar Items

Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome
by: Wang D, et al.
Published: (2022-04-01)

Comparison of Outcome of Metformin And Inositol on Hormonal Aspects in Women with Polycystic Ovaries: A Quasi-Experimental Study
by: Namra Mazhar, et al.
Published: (2024-06-01)

Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
by: Christodoula Kourtidou, et al.
Published: (2023-02-01)

The Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS
by: Aleksandra Jaroń, et al.
Published: (2024-08-01)

Polycystic ovarian syndrome - management and treatment
by: Martyna Julia Kłosińska, et al.
Published: (2021-09-01)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)

Risk of schizophrenia in patients with polycystic ovary syndrome: a nationwide population-based cohort study from Taiwan
by: Shih-Fen Chen, et al.
Published: (2021-10-01)

Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review
by: Lingling Zhou, et al.
Published: (2023-11-01)

Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis
by: Huamin Zeng, et al.
Published: (2023-08-01)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
by: Yumie Takeshita, et al.
Published: (2022-06-01)

Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis
by: Haiying Cui, et al.
Published: (2022-03-01)

The Protective Effects of Trans-Anethole against Polycystic Ovary Syndrome Induced Histopathological and Metabolic Changes in Rat
by: Faezeh Moradi Negahdari, et al.
Published: (2022-07-01)

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension
by: Hae Young Lee, et al.
Published: (2024-09-01)

Positive effect of vitamin D supplementation on weight loss in obese patients treated with glucagon-like peptide 1 and lifestyle interventions
by: M.B. Gorobeiko, et al.
Published: (2022-09-01)

Comparison of Metformin and Orlistat in Anovulatory, Overweight and Obese Women with Polycystic Ovarian Syndrome
by: Uzma Gul, et al.
Published: (2023-06-01)

Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
by: Andrea Etrusco, et al.
Published: (2024-03-01)

Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 month follow up period
by: H.A. El Maghraby, et al.
Published: (2015-09-01)

Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates
by: Pratap Kumar, et al.
Published: (2014-01-01)

Ovulation induction techniques in women with polycystic ovary syndrome
by: Andreas A. Vyrides, et al.
Published: (2022-08-01)

The effects of melatonin and metformin on histological characteristics of the ovary and uterus in letrozole-induced polycystic ovarian syndrome mice: A stereological study
by: Parvin Lohrasbi, et al.
Published: (2022-11-01)

Role of Metformin in Polycystic Ovary Syndrome
by: Karolina Nowak, et al.
Published: (2024-01-01)

Can glucose‐lowering medications improve outcomes in non‐diabetic heart failure patients? A Bayesian network meta‐analysis
by: Trevor Yeong, et al.
Published: (2022-04-01)

An integrated approach for obesity management: the effectiveness of glucagon-like peptide 1 agonist and life-style interventions for obesity management
by: A.V. Dinets, et al.
Published: (2022-05-01)

Recent advances in understanding the mechanisms in skeletal muscle of interaction between exercise and frontline antihyperglycemic drugs
by: Sean A. Newsom, et al.
Published: (2024-06-01)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes
by: Graciela Zambrano-Galván, et al.
Published: (2024-10-01)

The efficacy of metformin and eenatide in polycystic ovary syndrome (PCOS) patients
by: Sanggeeta Kesavan, et al.
Published: (2023-06-01)

Metabolic adverse effects of antipsychotics: the state of the problem and management options
by: A. V. Balashova, et al.
Published: (2023-04-01)

Metformin therapy in a hyperandrogenic anovulatory mutant murine model with polycystic ovarian syndrome characteristics improves oocyte maturity during superovulation
by: Sabatini Mary E, et al.
Published: (2011-05-01)

Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis
by: Mohamed E. A. Mostafa, et al.
Published: (2025-03-01)

Valproate Induced Obesity and Polycystic Ovaries
by: J Gordon Millichap
Published: (1996-06-01)

Combined Oral Contraceptives for Polycystic Ovary Syndrome: <i>Pro</i> and <i>Contra</i> (Review)
by: I. A. Mazerkina, et al.
Published: (2024-07-01)

Comparison of Therapeutic Effects in terms of Menstrual Irregularities between Statins and Metformin in Unmarried Patients with Polycystic Ovarian Syndrome
by: Sobia Nawaz, et al.
Published: (2023-08-01)

Myo-inositol versus metformin effects on clinical features, endocrine and metabolic profiles in infertile women with polycystic ovary syndrome: A randomized controlled trial
by: Nguyen Sa Viet Le, et al.
Published: (2023-01-01)

Effects of Lipoherb with Metformin on Metabolic Parameters and Sex Hormones in Rats with Polycystic Ovary Syndrome
by: Fatemeh Tavakoli, et al.
Published: (2023-03-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial
by: Ivan Koychev, et al.
Published: (2024-10-01)

Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics
by: Tetsuaki Inokuchi, et al.
Published: (2024-09-01)

GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
by: Jiani Zhong, et al.
Published: (2024-05-01)

Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
by: Francesco Natale, et al.
Published: (2024-05-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2018-12-01)